MBX Biosciences (NASDAQ:MBX) Reaches New 1-Year High – Time to Buy?

Posted by Brenda Bartman on Aug 7th, 2026

MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $71.12 and last traded at $70.70, with a volume of 695976 shares. The stock had previously closed at $64.41.

Wall Street Analysts Forecast Growth

MBX has been the topic of a number of research reports. Wall Street Zen raised shares of MBX Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of MBX Biosciences in a report on Friday, July 17th. Truist Financial raised their price target on shares of MBX Biosciences from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Citizens Jmp lifted their price target on shares of MBX Biosciences from $76.00 to $86.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 12th. Finally, Barclays upped their price target on shares of MBX Biosciences from $66.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, MBX Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $71.12.

Check Out Our Latest Stock Analysis on MBX Biosciences

MBX Biosciences Price Performance

The business’s fifty day simple moving average is $51.47 and its 200 day simple moving average is $39.83. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -30.37 and a beta of 0.10.

MBX Biosciences (NASDAQ:MBX – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.10). As a group, equities analysts forecast that MBX Biosciences, Inc. will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On MBX Biosciences

Several institutional investors have recently made changes to their positions in MBX. Candriam S.C.A. bought a new stake in MBX Biosciences in the 1st quarter valued at about $8,787,000. Eventide Asset Management LLC bought a new stake in shares of MBX Biosciences during the fourth quarter valued at approximately $28,071,000. Stempoint Capital LP boosted its position in shares of MBX Biosciences by 535.8% during the first quarter. Stempoint Capital LP now owns 499,469 shares of the company’s stock worth $14,909,000 after buying an additional 420,916 shares during the period. Swiss National Bank bought a new position in MBX Biosciences in the 1st quarter worth approximately $1,325,000. Finally, Seven Fleet Capital Management LP acquired a new stake in MBX Biosciences in the 4th quarter valued at approximately $574,000.

MBX Biosciences Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.